BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, February 22, 2026
Home » Blogs » BioWorld MedTech Perspectives » Proton beams and the media

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Proton beams and the media

May 17, 2012
By Mark McCarty

As a member of the media, I’m not exactly unaware of the pitfalls of my profession but it might be time to take a look at some of the coverage of proton beam therapy in recent months.

Frankly, most of the mainstream media coverage failed to paint a complete picture and in the process trampled on vital details. On the other hand, some hospitals perhaps could use a lesson in basic economics because you don’t have to install a $300 million cyclotron facility to get protons in your hospital or clinic.

Click here for an example of mainstream media coverage that utterly fails to note the availability of systems that ring in at less than $100 million. Harold Brubaker’s April 29 piece mentions systems coming in for more than $300 million. He’s not alone in that omission, however.

So what’s the problem?

Hospitals in a hurry to spend more?

The problem for hospitals is that they’re dashing off to find the nearest provider of proton beam capability, for one thing. The other problem is that Brubaker doesn’t bother to put enough work into his trade to discuss the availability of much less expensive hardware that requires a much smaller footprint than the traditional cyclotron set-up.

For instance, as I wrote in the April 11 edition of Medical Device Daily, the Radiance 330, made by Protom, can be installed for roughly $50 million. Hospital administrators who feel that’s too much might consider waiting a couple of years to see if the dielectric wall accelerator under development by Compact Particle Accelerator gets through development and an FDA scrub-down. This approach might require a generator of about 15 feet in its longest dimension, and the firm projects a total cost – infrastructure included – of something in the neighborhood of $30 million.

Nearly fired for misbehaving, Levy mouths off

Here’s an example of the worst possible coverage. One article quoted Paul Levy, formerly the president of Beth Israel Deaconess Medical Center, as saying the success of proton beam therapy was simple. “The easiest group to market to in the country is a group of men worrying about the functioning of their penis,” Levy said, according to a March 26 Bloomberg story.

I dare Levy to make a similarly cavalier remark about any part of a woman’s anatomy, especially since he nearly lost his job at Deaconess in 2010 because of an inappropriate relationship with a woman who worked for him. Massachusetts’ attorney general Martha Coakley is quoted as having said that Levy’s relationship with the woman “clearly endangered the reputation of the institution and its management.” He resigned a year later.

Leave it to the mainstream press to quote someone with that much irony-laden baggage.

I know I’m horribly geeky about some things, and I’m especially geeky about things I don’t understand at all, such as protons. But I do understand two things. One is that $30 million is a lot less loot than $300 million – even the kid who throws cereal at Jimmy Fallon knows that – and the other is that if you’re too lazy to tell more than half the story, you really are not very good at what you’re paid to do.

Popular Stories

  • Today's news in brief

    BioWorld
  • IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

    BioWorld Science
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • Illustration of head with maze that is missing parts

    Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

    BioWorld Science
    Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
  • Illustration of brain and antibodies

    VST Bio’s VB-001 is neuroprotector after stroke

    BioWorld Science
    At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing